Inclusion Criteria:

        (Part 1)

        -Documented incurable/locally advanced or metastatic solid tumors that have either relapsed
        or are refractory or intolerant to standard therapies of proven clinical benefit.

        (Part 2) Meets 1 of the 3 defined cohorts:

          -  Cohort 1: Documented incurable/locally advanced or metastatic clear cell renal cell
             carcinoma (ccRCC)

          -  Cohort 2: Documented incurable/locally advanced or metastatic triple-negative breast
             cancer (TNBC) defined as estrogen receptor (ER), progesterone receptor (PR) negative
             (<1%) and human epidermal growth factor receptor 2 (HER2) negative
             (immunohistochemistry 0 to 1+ or fluorescence in situ hybridization [FISH] negative)

          -  Cohort 3: incurable/locally advanced or metastatic CRC

        For both Parts 1 & 2:

          -  Recovery to baseline or ≤ Grade 1 Common Terminology Criteria for Adverse Events
             (CTCAE) v.5.0 from toxicities related to the prior therapy

          -  Adequate renal, hepatic, and hematological function

          -  Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 evaluable disease
             (Part 1) or measurable disease (Part 2)

          -  Ability to provide written consent in accordance with federal, local and institutional
             guidelines

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

        Exclusion Criteria for both Parts 1 & 2:

          -  Prior treatment with CB-839 or a PARP inhibitor

          -  Unable to received oral medications

          -  Active and/or untreated central nervous system metastasis. Patients with treated brain
             metastases must have (1) documented radiographic stability of at least 4 weeks
             duration demonstrated on baseline central nervous system (CNS) imaging prior to study
             treatment and (2) be symptomatically stable and off steroids for at least 2 weeks
             before administration of any study treatment.

          -  Major surgery within 28 days prior to first dose of study drug

          -  Receipt of any anticancer therapy within the following windows: small molecule
             tyrosine kinase inhibitor therapy (including investigational) within the prior 2 weeks
             or 5 half-lives prior to C1D1, whichever is longer; any type of anti-cancer antibody
             or cytotoxic chemotherapy within 4 weeks prior to C1D1; radiation therapy for bone
             metastasis within 2 weeks prior or any other external radiation therapy within 4 weeks
             prior to C1D1; patients with clinically relevant ongoing complications from prior
             radiation therapy are not eligible.